Evidence map›Paper›PMID 40295014›Full record

ArticleIn vivo (Athens, Greece)

Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma.

Nobuki Furubayashi, Manabu Mochida, Atsuhiro Kijima, Yushi Fujimoto, Motonobu Nakamura, Takahito Negishi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nobuki FurubayashiDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan furubayashi.nobuki.yc@mail.hosp.go.jp.
Manabu MochidaDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Atsuhiro KijimaDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Yushi FujimotoDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Motonobu NakamuraDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Takahito NegishiDepartment of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe impact of steroid premedication on the efficacy and cutaneous toxicity of enfortumab vedotin (EV) in advanced urothelial carcinoma (UC) is unclear. PATIENTS AND

methodsWe retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to November 2024.

resultsTwenty-eight patients (male, n=16; median age, 71 years) were enrolled. Dexamethasone 6.6 mg was administered intravenously prior to EV in six (21.4%) patients. There were no differences in the overall response and disease control rates between patients with and without steroid premedication (

conclusionIn EV treatment, steroid premedication did not affect clinical outcomes. The incidence and severity of EV-related cutaneous toxicity tended to improve in patients who received steroid premedication, although no significant differences were observed.

Indexed as

Antibodies, MonoclonalPremedicationSteroidsUrologic NeoplasmsAgedAged, 80 and overDexamethasoneFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalDexamethasoneenfortumab vedotinSteroidscutaneous toxicityenfortumab vedotinsteroid premedicationUrothelial carcinoma

Identifiers

PMID40295014
PMCPMC12041992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.